JP2000512273A - 高収率立体特異性マンノシル化 - Google Patents
高収率立体特異性マンノシル化Info
- Publication number
- JP2000512273A JP2000512273A JP09542741A JP54274197A JP2000512273A JP 2000512273 A JP2000512273 A JP 2000512273A JP 09542741 A JP09542741 A JP 09542741A JP 54274197 A JP54274197 A JP 54274197A JP 2000512273 A JP2000512273 A JP 2000512273A
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- alkyl
- formula
- compound
- aralkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000005621 mannosylation reaction Methods 0.000 title description 4
- 230000000707 stereoselective effect Effects 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- ATMYEINZLWEOQU-QTVWNMPRSA-N (3S,4S,5S,6R)-2-fluoro-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1OC(F)[C@@H](O)[C@@H](O)[C@@H]1O ATMYEINZLWEOQU-QTVWNMPRSA-N 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000002841 Lewis acid Substances 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 150000007517 lewis acids Chemical class 0.000 claims description 4
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims 2
- 239000000126 substance Substances 0.000 abstract description 5
- 239000011968 lewis acid catalyst Substances 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- -1 ethoxy, benzyl Chemical group 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000003800 Selectins Human genes 0.000 description 4
- 108090000184 Selectins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 108010035766 P-Selectin Proteins 0.000 description 3
- 102100023472 P-selectin Human genes 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 150000002905 orthoesters Chemical class 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 108010024212 E-Selectin Proteins 0.000 description 2
- 102100023471 E-selectin Human genes 0.000 description 2
- 229920002274 Nalgene Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- JJXATNWYELAACC-DGTMBMJNSA-N [(2r,3r,4s,5s,6r)-3,4,5-triacetyloxy-6-fluorooxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@H](F)[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O JJXATNWYELAACC-DGTMBMJNSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- ATMYEINZLWEOQU-PQMKYFCFSA-N (2r,3s,4s,5s,6r)-2-fluoro-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@H](F)[C@@H](O)[C@@H](O)[C@@H]1O ATMYEINZLWEOQU-PQMKYFCFSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930185605 Bisphenol Natural products 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 101150044441 PECAM1 gene Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- NIGUVXFURDGQKZ-UQTBNESHSA-N alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O NIGUVXFURDGQKZ-UQTBNESHSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CNMFHDIDIMZHKY-UHFFFAOYSA-N methyl 2,2-dimethylpropanoate Chemical compound COC(=O)C(C)(C)C CNMFHDIDIMZHKY-UHFFFAOYSA-N 0.000 description 1
- NVGQWSWUBAGYKA-UHFFFAOYSA-N methyl 2-[3-[2-hydroxy-5-[6-[4-hydroxy-3-[3-(2-methoxy-2-oxoethyl)phenyl]phenyl]hexyl]phenyl]phenyl]acetate Chemical compound COC(=O)CC1=CC=CC(C=2C(=CC=C(CCCCCCC=3C=C(C(O)=CC=3)C=3C=C(CC(=O)OC)C=CC=3)C=2)O)=C1 NVGQWSWUBAGYKA-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000002412 selectin antagonist Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 150000008135 α-glycosides Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Steroid Compounds (AREA)
- Paper (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Organic Insulating Materials (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 式: [式中、Xは、アルキルまたはアリールであり、Rは、低級アルキル、分岐アル キル、アリール、アラルキル、またはOG[Gは、低級アルキル、分岐アルキル 、アリール、またはアラルキル]である。] で示される化合物の調製方法であって、式: [式中、Rは前記と同じ意味である。] で示される化合物を、ルイス酸の存在下において、式XOH[式中、Xは、アル キルまたはアリールである。]で示される化合物と反応させることを含んで成る 方法。 2. フッ化マンノシルを、三フッ化硼素−エーテレートの存在下において、ア ルコールまたはフェノールと反応させることによって、反応が実施される請求項 1に記載の方法。 3. Xが、 である請求項1に記載の方法。 4. Xが、である請求項1に記載の方法。 5. 式: [式中、Rは、低級アルキル、分岐アルキル、アリール、アラルキル、またはア ルコキシであるが、メチルではない。] で示される化合物。 6. XがOCH2CH3である請求項5に記載の化合物。 7. XがCH2PHである請求項5に記載の化合物。 8. XがCH(CH3)2である請求項5に記載の化合物。 9. XがC(CH3)3である請求項5に記載の化合物。 10. 式: [式中、Rは、低級アルキル、分岐アルキル、アリール、アラルキル、またはア ルコキシであり、Sは、アルキルまたはアリールである。] で示される化合物。 11. 式:[式中、Rは、低級アルキル、分岐アルキル、アリール、アラルキル、またはア ルコキシであり、Sは、アルキルまたはアリールである。] で示される化合物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/650,653 | 1996-05-20 | ||
| US08/650,653 US5712387A (en) | 1996-05-20 | 1996-05-20 | High yield stereospecific mannosylation |
| PCT/US1997/008726 WO1997044344A1 (en) | 1996-05-20 | 1997-05-20 | High yield stereospecific mannosylation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000512273A true JP2000512273A (ja) | 2000-09-19 |
| JP4412743B2 JP4412743B2 (ja) | 2010-02-10 |
Family
ID=24609746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP54274197A Expired - Fee Related JP4412743B2 (ja) | 1996-05-20 | 1997-05-20 | 高収率立体特異性マンノシル化 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5712387A (ja) |
| EP (1) | EP0912587B1 (ja) |
| JP (1) | JP4412743B2 (ja) |
| AT (1) | ATE259822T1 (ja) |
| AU (1) | AU712905B2 (ja) |
| CA (1) | CA2255666C (ja) |
| DE (1) | DE69727680T2 (ja) |
| ES (1) | ES2216152T3 (ja) |
| PT (1) | PT912587E (ja) |
| WO (1) | WO1997044344A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012017306A (ja) * | 2010-07-09 | 2012-01-26 | Central Glass Co Ltd | 2,3,4,6−テトラ−o−アシル−d−マンノピラノシルフルオリド高純度品の工業的製造方法 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1897533A1 (en) * | 2006-09-08 | 2008-03-12 | Revotar Biopharmaceuticals AG | Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions |
| EP1903049A1 (en) * | 2006-09-08 | 2008-03-26 | Revotar Biopharmaceuticals AG | Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyloxy)-phenyl] hexane |
| KR20130056238A (ko) * | 2010-05-07 | 2013-05-29 | 레보타 바이오파마슈티컬스 아게 | 비모시아모스의 제조 방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3626028A1 (de) * | 1985-09-14 | 1987-03-19 | Hoechst Ag | Verfahren zur herstellung von am sauerstoff geschuetzten glycosylfluoriden |
| EP0267996A1 (en) * | 1986-11-20 | 1988-05-25 | Tamir Biotechnology Ltd. | New nucleotide derivatives |
| JPH02144151A (ja) * | 1988-11-22 | 1990-06-01 | Dainippon Ink & Chem Inc | グリコシド縮合用触媒及びアリールグリコシド類の製造方法 |
| EP0373118A3 (de) * | 1988-12-07 | 1991-10-16 | Ciba-Geigy Ag | Verfahren zur Herstellung von geschützten Mono- und Oligozuckerhalogeniden |
| JP2774417B2 (ja) * | 1991-08-07 | 1998-07-09 | 株式会社ディ・ディ・エス研究所 | ペプチド骨格を有する分枝鎖型糖複合体及び微粒子キャリヤー |
| JP2710900B2 (ja) * | 1992-09-02 | 1998-02-10 | 株式会社ディ・ディ・エス研究所 | 酸性官能基を有する脂質誘導体及び同誘導体によって被覆された微粒子キャリヤー |
| DE4329093A1 (de) * | 1993-08-30 | 1995-03-02 | Bayer Ag | Substituierte Aminoalkylglycoside |
-
1996
- 1996-05-20 US US08/650,653 patent/US5712387A/en not_active Expired - Lifetime
-
1997
- 1997-05-20 EP EP97925707A patent/EP0912587B1/en not_active Expired - Lifetime
- 1997-05-20 AT AT97925707T patent/ATE259822T1/de active
- 1997-05-20 ES ES97925707T patent/ES2216152T3/es not_active Expired - Lifetime
- 1997-05-20 PT PT97925707T patent/PT912587E/pt unknown
- 1997-05-20 DE DE69727680T patent/DE69727680T2/de not_active Expired - Lifetime
- 1997-05-20 JP JP54274197A patent/JP4412743B2/ja not_active Expired - Fee Related
- 1997-05-20 CA CA002255666A patent/CA2255666C/en not_active Expired - Fee Related
- 1997-05-20 WO PCT/US1997/008726 patent/WO1997044344A1/en not_active Ceased
- 1997-05-20 AU AU30766/97A patent/AU712905B2/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012017306A (ja) * | 2010-07-09 | 2012-01-26 | Central Glass Co Ltd | 2,3,4,6−テトラ−o−アシル−d−マンノピラノシルフルオリド高純度品の工業的製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU712905B2 (en) | 1999-11-18 |
| US5712387A (en) | 1998-01-27 |
| CA2255666A1 (en) | 1997-11-27 |
| WO1997044344A1 (en) | 1997-11-27 |
| CA2255666C (en) | 2007-07-31 |
| EP0912587A1 (en) | 1999-05-06 |
| ES2216152T3 (es) | 2004-10-16 |
| EP0912587B1 (en) | 2004-02-18 |
| JP4412743B2 (ja) | 2010-02-10 |
| EP0912587A4 (en) | 2001-12-19 |
| DE69727680D1 (de) | 2004-03-25 |
| DE69727680T2 (de) | 2004-12-02 |
| ATE259822T1 (de) | 2004-03-15 |
| AU3076697A (en) | 1997-12-09 |
| PT912587E (pt) | 2004-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4710491A (en) | N-glycosylated carboxylic acid derivatives as agents for combating rheumatic diseases | |
| HUP0102670A2 (hu) | Kapszulázott, reakcióképes komponenseket tartalmazó fogápoló készítmény | |
| US4797477A (en) | Process for preparing sialic acid derivatives | |
| Van Boeckel et al. | Synthesis of phosphatidyl-β-glucosyl glycerol containing a dioleoyl diglyceride moiety: Application of the tetraisopropyldisiloxane-1, 3-diyl (tips) protecting group in sugar chemistry. part IV | |
| JP3231765B2 (ja) | デメチルエピポドフィロトキシンの製造方法 | |
| CA1267891A (en) | Process for the preparation of sphingosine derivatives | |
| E. Aly et al. | The Dimethylmaleoyl Group as Amino Protective Group–Application to the Synthesis of Glucosamine‐Containing Oligosaccharides | |
| JP4412743B2 (ja) | 高収率立体特異性マンノシル化 | |
| JPH0567640B2 (ja) | ||
| JPH0592987A (ja) | 4′−デメチルエピポドフイロトキシングリコシド類 | |
| JP3170280B2 (ja) | 新規かつ改良されたエーテル性置換保護モノサッカライドの溶媒不在合成方法およびそれらの選択的加水分解 | |
| KR100609799B1 (ko) | 고수율입체특이성만노스화 | |
| US6620921B1 (en) | Glucofuranoses | |
| JPH02292295A (ja) | エトポシドの製造方法 | |
| JP3037445B2 (ja) | レチニルグルコシドの製法 | |
| HU217114B (hu) | Új monoszacharidszármazékok, ilyen vegyületeket tartalmazó gyógyászati készítmények és eljárás ezek előállítására | |
| KR100519498B1 (ko) | 에토포사이드의 제조방법 | |
| JP2625620B2 (ja) | フコシル‐グルコサミン誘導体 | |
| Morikawa et al. | Novel Partial Protections of 1, 6–Anhtdro–β-Lactose | |
| JP2812981B2 (ja) | ジサッカライド誘導体の中間体及びその製造法 | |
| Capozzi et al. | Selective Glycosidation Reactions and Their Use in Medicinal Chemistry | |
| DE DK et al. | VERFAHREN ZUR HERSTELLUNG VON ETOPOSID PROCEDE DE PREPARATION D’ETOPOSIDE | |
| US20070135358A1 (en) | Steroid modified solatrioses | |
| Reed III et al. | SYNTHESIS OF THIOLACTOSE 4-S-(| 3-D-GALACTOPYRANOSYL)-4-THIO-D-GLUCOPYRANOSIDE | |
| JPH09241288A (ja) | グリコシル化合物の立体選択的な製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040401 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080212 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080226 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080519 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080630 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080822 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090331 |
|
| A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20090702 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20090702 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090723 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090811 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20091008 Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20091008 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091027 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091117 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121127 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131127 Year of fee payment: 4 |
|
| LAPS | Cancellation because of no payment of annual fees |